Bio-Techne Announces Travel Grants to Attend FENS 2016

Eleonora Vianello, PhD Student
Trieste, Italy

Ellen Ji, PhD Student
Randwick, Austrailia

Gabriele Lignani, Postdoctoral Fellow
London, UK

Meike Diepenbroek, Postdoctoral Fellow
Lund, Sweden

Philip Adeniyi, Lecturer I
Ado-Ekiti, Nigeria
Juan Garcia Revilla, PhD Student
Seville, Spain

Kelly Duong, Graduate Student
Seattle WA, USA

Abdelaziz Ghanemi, PhD Student
Québec, Canada

Carsten Finke, Assistant Professor
Berlin, Germany

Daniela Puzzo, Assistant Professor
Catania, Italy

Terms and Conditions:

  1. Travel grants will be awarded to support attendance at FENS 2016, held in Copenhagen, Denmark July 2-6, 2016 and no other event.
  2. All applications must be submitted to Bio-Techne via the online application form between February 10, 2016 and March 31, 2016.
  3. Any researcher from an academic or non-profit institution is eligible to apply (technicians, PhD/graduate students, post-docs, principal investigators).
  4. Authorship on an abstract at FENS 2016 is not required.
  5. Applicants must complete the application form in full.
  6. Travel grants will not be awarded to employees of for-profit organizations (i.e. biotech or pharmacological companies).
  7. Travel grant recipients will be determined via a random drawing by Bio-Techne.
  8. The recipients will be contacted by email on April 7, 2016 and also announced online.
  9. Travel grants will be paid to the laboratory of the award recipient's principal investigator (PI) via the parent university or institution. If paid directly to the PI of the lab, taxes may apply.
  10. Proof of attendance at FENS 2016 will be required prior to travel grant payment.
  11. By submitting this application, you agree to receive information from Bio-Techne brands (R&D Systems, Tocris Bioscience and Novus Biologicals), including distributors. Your information will never be sold or used by a third party. See our complete Privacy Policy for more information.


Hello Sir/ Ma'am,

While submitting the abstract for the FENS Forum of Neurossience, I forgot to add the authorship. Will you please let me know if I need to resubmit?

Thanks and regards,



Effects of Caffeic Acid Phenethyl Ester (CAPE) on neurite outgrowth in PC12 and protection of dopaminergic neurons in-vivo model of Parkinson Disease.

Silva, RB; dos Santos NA, Martins, NM; Ferreira RS; Sisti FM; Del-Bel E; dos Santos AC.

Parkinson's disease (PD) is a progressive, degenerative disease of the central nervous system (CNS) characterized by loss of dopaminergic neurons of the substantia nigra associated with typical motor manifestations, such as: tremors, stiffness, slow movement (bradykinesia) and difficulty to walk. A serial studies showed that PD is triggered by inflammation processes. Agents such as Caffeic Acid Phenethyl Ester (CAPE) has been showed with an evident anti-inflammatory and thus the CAPE would be a possible promising therapeutic agent. Moreover the neurite loss is an early event in neurodegenerative diseases; therefore, the regeneration of the network of neurites constitutes an interesting strategy of treatment for such disorders. Neurotrophic factors play a critical role in neuronal regeneration, but their clinical use is limited by their inability to cross the blood brain barrier. Thus the present study demonstrates that CAPE protects PC12 cells from the cellular death induced by the dopaminergic neurotoxin MPP(+) by increasing the network of neurites and parallel way this study show the protects effects of CAPE on model in-vivo of Parkinson`s Disease. Therefore this study supports the findings of the CAPE acts by activating neuroplasticity processes leading to neuroprotection. These findings have been observed in in-vivo model, through the protection of dopaminergic neurons, the CAPE as in-vitro through neurite outgrowth.

Keywords: CAPE (caffeic acid phenethyl ester); GAP-43; Neuroprotection; Synapsin I; Synaptophysin